The latest price target for Biolase Inc COM PAR $.001 NEW (OTC:BIOL) was reported by Benchmark on October 2, 2024. The analyst firm set a price target for $0.40 expecting BIOL to rise to within 12 months (a possible 488.24% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Biolase Inc COM PAR $.001 NEW (OTC:BIOL) was provided by Benchmark, and Biolase Inc COM PAR $.001 NEW reiterated their speculative buy rating.

There is no last upgrade for Biolase Inc COM PAR $.001 NEW

There is no last downgrade for Biolase Inc COM PAR $.001 NEW.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biolase Inc COM PAR $.001 NEW, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biolase Inc COM PAR $.001 NEW was filed on October 2, 2024 so you should expect the next rating to be made available sometime around October 2, 2025.

While ratings are subjective and will change, the latest Biolase Inc COM PAR $.001 NEW (BIOL) rating was a reiterated with a price target of $0.40 to $0.40. The current price Biolase Inc COM PAR $.001 NEW (BIOL) is trading at is $0.07, which is out of the analyst’s predicted range.